Immunotherapy plus a targeted drug for rare genitourinary tumors
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have cancer that has spread (metastatic) or is getting worse on scans.
- Your cancer type must match one of the study’s rare genitourinary tumor groups (based on tumor biopsy/pathology).
- You must have at least one measurable spot of cancer, and for the “bone-only” group you must have bone confirmation on a bone scan.
- You must be well enough to get treatment: Karnofsky performance score at least 80%, and blood counts/liver/kidney labs must be within allowed limits.
- You must be able to swallow the study tablets, and be free of certain recent treatments/medical problems (like recent strong immune therapy, recent chemo, certain radiation timing, uncontrolled bowel issues, or active bleeding).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests a combination of three drugs (enfortumab vedotin, pembrolizumab, and quemliclustat) for people with bladder or upper urinary tract cancer that has spread or cannot be removed by surgery. It aims to see if this combination can shrink tumors and help patients live longer.
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) for people with certain rare cancers of the urinary tract or testicles. The goal is to see if these treatments can shrink tumors or stop them from growing.
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
Hear when a new Chromophobe Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.